^
    Apply
    Study of the Theranostic Pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to Identify and Treat Subjects with GPC3+ Unresectable HCC (NCT06726161)
    Phase 1
    RayzeBio, Inc.
    Recruiting
    Last update posted :
    12/10/2024
    Initiation :
    12/01/2024
    Primary completion :
    03/01/2029
    Completion :
    01/01/2031
    GPC3
    Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (NCT05450562)
    Phase 1/2
    Sanofi
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    09/20/2022
    Primary completion :
    12/12/2030
    Completion :
    12/12/2030
    ALK • GPC3
    |
    GPC3 expression • GPC3 positive
    |
    Tecentriq (atezolizumab) • Libtayo (cemiplimab-rwlc) • SAR444200
    T-Cell Therapy (ECT204) in Adults With Advanced HCC (ARYA3) (NCT04864054)
    Phase 2
    Eureka Therapeutics Inc.
    Recruiting
    Last update posted :
    05/06/2024
    Initiation :
    03/11/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    GPC3
    |
    GPC3 expression • GPC3 positive
    |
    cyclophosphamide • Stivarga (regorafenib) • ECT204
    A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma (NCT05022927)
    Phase 1
    Chugai Pharmaceutical
    Recruiting
    Last update posted :
    02/12/2024
    Initiation :
    06/01/2021
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    GPC3
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Actemra IV (tocilizumab) • ERY974
    NWRD06 DNA Plasmid for HCC After Radical Resection (NCT06088459)
    Phase 1
    Newish Technology (Beijing) Co., Ltd.
    Recruiting
    Last update posted :
    10/18/2023
    Initiation :
    11/01/2023
    Primary completion :
    12/01/2024
    Completion :
    06/01/2025
    GPC3
    |
    GPC3 positive
    A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment (NCT04928677)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/28/2023
    Initiation :
    06/09/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2025
    GPC3
    |
    GPC3 expression
    |
    codrituzumab (RG7686)
    A Study of CM350 in Patients With Advanced Solid Tumors (NCT05263960)
    Phase 1/2
    Keymed Biosciences Co.Ltd
    Recruiting
    Last update posted :
    06/09/2022
    Initiation :
    04/21/2022
    Primary completion :
    03/01/2025
    Completion :
    03/01/2025
    GPC3
    |
    GPC3 positive
    |
    CM350
    Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer (BK2016.01) (NCT03146637)
    Phase 2
    Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
    Recruiting
    Last update posted :
    02/01/2021
    Initiation :
    05/01/2017
    Primary completion :
    01/27/2021
    Completion :
    01/28/2021
    GPC3
    |
    activated CIK and bispecific antibody • activated CIK-anti-CD3/MUC1/CEA/EpCAM/GPC3 antibody
    A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma (NCT01507168)
    Phase 2
    Hoffmann-La Roche
    Completed
    Last update posted :
    04/03/2020
    Initiation :
    02/02/2012
    Primary completion :
    08/20/2015
    Completion :
    08/20/2015
    GPC3
    |
    GPC3 expression
    |
    codrituzumab (RG7686)
    A Study of ERY974 in Patient With Advanced Solid Tumors (NCT02748837)
    Phase 1
    Chugai Pharmaceutical
    Completed
    Last update posted :
    08/22/2019
    Initiation :
    08/01/2016
    Primary completion :
    08/01/2019
    Completion :
    08/01/2019
    GPC3
    |
    GPC3 positive
    |
    ERY974